Channels

Top 100 Trending New

Categories

Crypto Gaming News Entertainment Music Sports Tech Gambling Bots and mini apps Finance Business Education Lifestyle Health Travel Auto Fashion Jobs Dating Deals and shopping

Stickers

Stickers Emoji Themes Wallpapers

Bots Gifts Tools

Currency

$ USD ₽ RUB € EUR ₴ UAH ₸ KZT ₺ TRY zł PLN ₪ ILS AED AED R$ BRL Rp IDR RM MYR ¥ JPY ₩ KRW CN¥ CNY

Theme

Português (Brasil)

Bahasa Indonesia

Беларуская

Українська

Channels Categories Stickers Bots Gifts Tools

Premium Wiki Glossary Legal

Notifications Settings Log in

CONCALLS: post #10164 — TG.ME

CONCALLS@Concalls3 · 10.1K subscribers Open in TelegramOpen

Forwarded fromDA

t.me/Concalls3/10164

4

2

September 7, 2026 624 3

More from this channel

FINEOTEX CHEMICAL | CRUDECHEM SCALE-UP + US OILFIELD CHEMICALS BUSINESS TRANSFORMATION - Fineotex operates across textile chemicals, cleaning & hygiene and oilfield chemicals, with manufacturing operations in India, Malaysia and the US. - The 53% CrudeChem acquisition in December 2025 has materially changed the business mix. - Oil & gas chemicals contributed ~65% of consolidated revenue and ~55% of volumes in Q1 FY27. - CrudeChem provides specialised, tailor-made chemistries for demanding oilfield applications rather than commodity products. MOAT & PRICING POWER - US oilfield chemical customers have long qualification cycles; new products and personnel can take up to 2 years to qualify with customers such as Shell, ExxonMobil and Halliburton. - CrudeChem's Trackmax logistics arm provides integrated last-mile delivery, an important capability because oil production cannot simply stop once a well is operating. - Solutions are customised, supporting better pricing power than commodity chemicals. - Raw-material increases can be passed through via separate war and fuel surcharges. - More than 100 product categories diversify the portfolio. MARGIN TRANSITION - Consolidated EBITDA margin was 15.7% in Q1 FY27. - Consolidation of CrudeChem has temporarily diluted Fineotex's historical standalone textile EBITDA margins of ~18–28%. - CrudeChem currently operates at ~13–14% EBITDA margins, with management targeting ~15%. - Successful integration and operating leverage could lift consolidated EBITDA margins toward 18–20%. - The key margin opportunity is converting CrudeChem from a lower-margin, undercapitalised business into a more efficient integrated platform. US OILFIELD — BIGGEST GROWTH ENGINE - Management has accelerated the $200 Mn oilfield revenue target from 2030 to FY28. - Texas facility has 148,000 MTPA capacity and was operating at ~63% utilisation in Q1 FY27 on a single shift. - Running double shifts could potentially increase utilisation by another 30–40% without significant new capex. - Fineotex plans to cross-sell its technologies through CrudeChem's existing customer network. - By FY28, oil & gas is expected to become the dominant business. FY28–FY30 AMBITION - Management sees potential for 3x–4x top-line growth toward ~₹3,000 Cr. - Growth would be driven by Texas capacity utilisation, CrudeChem scale-up, cross-selling and margin improvement. - Legacy textile chemicals could also recover as zero-duty access to the UK/EU supports Indian textile exports. - Fineotex intends to increase its CrudeChem ownership from 53% to ~79–80% by January 2028. CAPEX & BALANCE SHEET - Fineotex invested ~$7 Mn in machinery after completing the CrudeChem acquisition. - Additional expansion capex over the next two years is expected at ~₹70–80 Cr. - Company remains debt-free, with >₹340 Cr cash as of Q3 FY26. - Growth is being funded through internal accruals and warrant conversions, including ₹35.68 Cr raised through warrants. - Capital allocation remains relatively conservative despite the aggressive growth strategy. KEY RISKS / FALSIFIERS - The biggest risk is execution of the rapid US scale-up. - CrudeChem must reach the $200 Mn FY28 revenue target while improving EBITDA margin from ~13–14% toward ~15%. - Rapid growth could increase working-capital requirements; maintaining the current ~72-day cycle is important. - US operations already contribute ~65% of consolidated revenue, increasing exposure to regional weather disruptions and oilfield demand cycles. - The ambitious 3x–4x revenue target depends heavily on successfully utilising the expanded Texas capacity. - If CrudeChem margins remain structurally low, consolidated margin expansion toward 18–20% could be difficult. KEY TAKEAWAY - CrudeChem + Texas capacity utilisation + margin expansion could transform Fineotex into a ₹3,000 Cr global specialty-chemicals platform, but US execution is the key risk. Stock Fundamental in detail @Fundamental3 1.7K·Sep 5 MAHARASHTRA SEAMLESS | CAPACITY EXPANSION + PREMIUM PIPE MIX BUSINESS & MOAT - India's leading manufacturer of seamless and ERW steel pipes, with oil & gas contributing ~70% of dispatches. - Market leader for ~35 years; domestic peers have largely gone through bankruptcy or restructuring. - High entry barriers from API certifications, long customer qualification cycles and established PSU relationships. - ONGC and Oil India account for ~42% of the order book. - Full product basket includes value-added cold drawn, drill and sour service pipes. - Japanese licensing agreement for premium connections adds another qualification barrier. - Anti-dumping duties provide some protection against Chinese imports. CAPACITY & UTILISATION - Active capacity stands at 5.5 lakh tons, with another 1 lakh tons of dormant capacity. - Telangana finishing line is expected to unlock the 1 lakh ton dormant capacity, taking total capacity to 6.5 lakh tons. - Cold drawn pipes are already operational with two draw benches. - Premium connections production is expected to start within six months from February 2026. - By mid-2028, utilisation could reach 80–85%, with annual dispatches of 4.5–5 lakh tons versus 4.12 lakh tons in FY26. MARGIN & PRODUCT MIX - EBITDA/ton has historically ranged between ₹8,000–15,000. - Q1 FY27 EBITDA/ton reached ₹15,600, supported by favourable product mix. - Premium connections and cold drawn products should improve the mix and support ₹12,000–15,000 EBITDA/ton. - At 4.5 lakh tons dispatches and ₹12,000–15,000 EBITDA/ton, EBITDA could potentially exceed ₹1,000 Cr by FY28 versus ~₹700 Cr in FY26. ORDER BOOK & DEMAND - Order book increased from ₹1,149 Cr in June 2025 to ₹1,709 Cr in August 2026. - Oil-sector orders account for ~42% of the order book. - Exports increased sharply to 22% of Q1 FY27 dispatches versus <10% in FY26. - Revival in oil & gas capex and PSU tender activity remains important for volume growth. - Management is conserving cash for potential distressed acquisitions, although no deal has been announced. FINANCIAL STRENGTH - Treasury/cash and investments stand at ~₹3,115 Cr, providing significant financial flexibility. - Company maintains a dividend policy while retaining substantial liquidity. - Strong balance sheet provides optionality for acquisitions and capacity investments. EXECUTION — WHAT TO WATCH - Telangana finishing line timeline has slipped from December 2025 to March 2026. - Hot-mill upgrade has not yet started. - Management has generally delivered near-term volume/earnings guidance, but project delays remain a monitorable. - The key near-term trigger is commissioning and ramp-up of the additional 1 lakh ton capacity. KEY RISKS - Anti-dumping duty is a major monitorable: current protection is expected to expire in October 2026, with a temporary extension to January 2027. - If duties are not renewed or strengthened, Chinese imports could pressure domestic prices and margins. - Delayed oil & gas capex or PSU tenders could slow volume growth. - Further delay in Telangana capacity could cap dispatch growth. - EBITDA/ton is cyclical and dependent on product mix and steel-price environment. KEY TAKEAWAY - ₹3,115 Cr treasury + 1 lakh ton capacity unlock + premium products could drive EBITDA toward ₹1,000 Cr by FY28, with anti-dumping policy and Telangana execution the key watchpoints. 1.4K·Sep 5 EXICOM TELE-SYSTEMS | TRITIUM TURNAROUND + CRITICAL POWER SCALE-UP BUSINESS & MOAT - Exicom operates across two key businesses: Critical Power systems for telecom sites and EV charging hardware through India operations + US subsidiary Tritium. - Critical Power contributed ₹177 Cr in Q1 FY27, +73% YoY, while standalone EV charging revenue was ₹61 Cr, +15% YoY. - Exicom has >50% share in India's wallbox charger market and ~60% share in the BharatNet government fibre project. - Deep qualification cycles and switching costs support the moat; telecom customers have worked with Exicom for ~30 years. - Consolidated order book stood at ₹1,400 Cr as of June 30, 2026. INDIA BUSINESS — STRONGER GROWTH - Standalone Q1 FY27 revenue was ₹234 Cr, +58% YoY, with EBITDA of ₹16 Cr. - Standalone EBITDA margin improved to 8.8% from 5.8% YoY; gross margin was 29.1%. - Hyderabad plant became fully operational in Q4 FY26 and triples production capacity. - Production is shifting from Gurgaon to Hyderabad over the next 2–3 months, eliminating ₹8.7 Cr of annualised parallel-run fixed costs. - Critical Power exports expected to rise from ~8% of sales in Q1 FY27 to ~15% by FY27-end. - BESS is expected to scale from near-zero to ~₹50 Cr revenue in FY27, supported by 15 MWh orders already won. - India business could compound at 20–30%, supported by telecom tower additions and EV penetration. TRITIUM — THE BIG TURNAROUND DRIVER - Consolidated EBITDA turned positive in Q4 FY26 for the first time since Tritium acquisition. - Tritium is targeting 3x revenue growth in FY27 and EBITDA breakeven by Q4 FY27. - Q1 FY27 Tritium bookings reached $20.8 Mn, around 2x the previous quarterly average; backlog was ~$20 Mn as of July 1. - Q1 FY27 Tritium revenue was ~$10.5 Mn; 3x FY27 growth implies roughly $120 Mn annualised revenue. - TRI-FLEX and other new products are under trials with Fortune 100 companies. - A successful hyperscaler qualification could create a $30–35 Mn FY28 revenue opportunity per product. - A $30 Mn firm Fortune 50 purchase order has already been secured, with deliveries beginning January 2026; a second ~$30 Mn annual RFP is advanced. - If product trials convert, FY28 Tritium revenue could potentially exceed $150 Mn. COST & MARGIN INFLECTION - Hyderabad consolidation should remove parallel-run costs and improve fixed-cost absorption. - Consolidated EBITDA breakeven is expected in Q2/Q3 FY27, while Tritium targets breakeven in Q4 FY27. - By mid-2028, management expects Hyderabad to be fully loaded, Tritium to reach triple-digit-million-dollar revenue and consolidated EBITDA margins to reach high-single digits or better. - If Tritium executes as guided, consolidated EBITDA could potentially reach ₹100–150 Cr by FY28. - FY26 VRS and retention costs were largely one-offs, while current PAT losses reflect fixed-cost absorption during the scale-up phase. ORDER BOOK & GROWTH VISIBILITY - Consolidated order book has reached ₹1,400 Cr. - Tritium bookings are accelerating, providing an important leading indicator for the turnaround. - New product launches during May–July 2026 create additional FY28 upside if customer qualifications convert. - Completed Hyderabad capex provides capacity for the next phase without requiring fresh equity dilution. MANAGEMENT EXECUTION — MIXED RECORD - Management had earlier guided 50% standalone revenue growth for FY26 but delivered only 19%. - Hyderabad plant commissioning slipped from October 2025 to March 2026. - However, consolidated EBITDA breakeven was achieved in Q4 FY26, reportedly a year ahead of the original Tritium timeline. - August 2026 management commentary reiterated consolidated EBITDA breakeven in Q2/Q3 FY27 and Tritium breakeven in Q4 FY27. KEY RISKS / KILL SHOT - The biggest risk is Tritium customer qualification and product-trial conversion. - Failure of hyperscaler trials or delays in new product launches could derail the 3x Tritium growth and Q4 FY27 breakeven targets. - Semiconductor and copper supply-chain volatility remains a risk. - Working capital could rise sharply through inventory and receivables. - Consolidated debt is ~₹370 Cr, so execution must translate into EBITDA and cash-flow improvement. - The key quarterly monitorable is Tritium bookings and progress toward the Q4 FY27 breakeven commitment. KEY TAKEAWAY - Tritium qualification + 3x revenue growth + Hyderabad scale-up could transform Exicom into a high-growth, profitable EV/critical-power platform. 5.2K·Sep 5

[media post] 1.2K·Sep 5 GMM PFAUDLER | MULTIPLE GROWTH CATALYSTS + MARGIN EXPANSION 1. HET — ORDER SURGE - Q1 FY27 order intake: ₹58 Cr, up >700% YoY. - EIL approvals received for Duplex, Super Duplex and air-cooled heat exchangers. - Vatva facility can potentially generate ₹700–800 Cr revenue with limited additional investment. - FY26 revenue was ~₹300 Cr, creating significant operating leverage. 2. EDLON — SEMICONDUCTOR GROWTH - Fluoropolymer business has scaled from US$10 Mn to US$25 Mn. - Won a US$8–9 Mn order in Q4 FY26. - New site being established to capture semiconductor-driven demand. - Business is high-margin and booked out for the year. - Also supplies PTFE-lined glove boxes to the US nuclear industry. 3. POLAND — LOW-COST MANUFACTURING HUB - Poland facility, GMM Inox (51% owned), is operating at full capacity. - Two additional sheds planned. - Revenue expected to nearly double to ~US$10 Mn over 2–3 years. - Dedicated low-cost workshop for Mavag and MIXEL. - New orders are increasingly being outsourced to Poland, supporting cost competitiveness. 4. GERMANY — RESTRUCTURING SAVINGS - German glass-lined facility agreed to reduce headcount by 30. - Phase-I savings expected at ~₹15–17 Cr in FY27. - Total potential savings expected to exceed ₹40 Cr. - Metal fabrication is being shifted toward lower-cost countries. - Further significant downsizing is not currently planned. 5. DEBT REDUCTION - Plans to repay ~€7 Mn debt by end-Q2 FY27. - Group-wide refinancing targeted over 12–18 months. - Objective: reduce interest costs and FX exposure. - Q1 FY27 finance costs already declined 47% YoY to ₹23 Cr. 6. NON-TRADITIONAL INDUSTRIES — HIGHER-VALUE MIX - Defence, nuclear, metals & minerals, oil & gas and semiconductors contributed 43% of FY26 order intake. - Up from 33% in FY25 and 31% in FY24. - These businesses carry higher EBITDA margins than the mature glass-lined segment. - Faster growth in these verticals can structurally improve the group's margin mix. 7. INDIA PHARMA / CDMO RECOVERY - Indian pharma glass-lined demand is improving strongly. - CDMO and peptide investments in Hyderabad are supporting new orders. - Q1 and Q2 FY27 demand outlook for glass-lined equipment is strong. - Indian CDMO market expected to expand significantly, supporting long-term equipment demand. 8. PEPTIDE SYSTEMS — NEW GROWTH VECTOR - Received two large Hyderabad orders for complete peptide-based systems. - Executing a large contract for a peptide manufacturer in South India. - Offers automated turnkey solutions for solid-phase peptide synthesis. - Mavag's Swiss technology strengthens GMM Pfaudler's positioning in peptide manufacturing systems. KEY TAKEAWAY HET scale-up + semiconductor/nuclear demand + restructuring savings + peptide systems could drive both growth and margin expansion. Must JOIN @Stockupdate9 1.3K·Sep 4

An open web layer over public Telegram — search, stats and channel reading right in your browser, no account, no install.

Not affiliated with Telegram FZ-LLC; all data comes from public sources.

Catalog

Top channels Categories Countries Search

Content

Stickers Emoji Gifts Themes Wallpapers

Help

Tools Wiki Glossary Blockchain Safety Premium Advertisers Advertising

© 2026 TG.ME · G.Media network· Updated 09/05/2026 · v0.2.0 · cd00242

Privacy Terms DMCA & complaints Report a violation

Similar channels

Wealthcreator40.7K subscribers

Fundamental Analysis (Long term)45K subscribers

BROKERAGE REPORTS23.2K subscribers

𝗟𝗼𝗻𝗴 𝗧𝗲𝗿𝗺 ®™21.7K subscribers

𝙎𝙝𝙤𝙧𝙩 𝙏𝙚𝙧𝙢®™30.9K subscribers

❁Stocks❁ ❁Result❁& BREAKING News21.1K subscribers

Learn With OM1.3K subscribers

Sridhar Balakrishnan 🇮🇳🏆💰13.3K subscribers